Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions

The Lancet Neurology

Volumn 17, Issue 10, 2018, Pages 842-

  Rato, Miguel Leal ^a   Duarte, Gonçalo S ^b   Mestre, Tiago ^c   de Carvalho, Mamede ^b,d   Ferreira, Joaquim J ^b,e  

^a Hospital Professor Doutor Fernando Fonseca   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e Campus Neurológico Sénior ^*  (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

NORPHENAZONE; RASAGILINE; RILUZOLE; INDAN DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; BACKACHE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FALLING; HEADACHE; HUMAN; LETTER; NOCEBO EFFECT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VERTIGO; DOUBLE BLIND PROCEDURE;

AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; HUMANS; INDANS; NOCEBO EFFECT; RILUZOLE;

EID: 85053464138     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(18)30310-7     Document Type: Letter

References (5)

1. Ludolph, AC, Schuster, J, Dorst, J, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol 17 (2018), 681–688.
2. Silva, MA, Duarte, GS, Camara, R, et al. Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology 88 (2017), 2216–2224.
3. Miller, RG, Mitchell, JD, Moore, DH, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev, 3, 2012 CD001447.
4. Abe, K, Aoki, M, Tsuji, S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16 (2017), 505–512.
5. European Medicines Agency. EMEA/H/C/000574-N/0078—summary of product characteristics Azilect. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000574/WC500030048.pdf, 2018. (Accessed 27 June 2018)